GlassScriptPhysician profile
Anita Eapen
NPI 1740643196
$2,756.26
in general payments reported to CMS, 2019-2025
19 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $352 · 2022: $1,188 · 2023: $912 · 2024: $131 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.73 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $888.16 | 2021-2025 | Gvoke Hypopen |
| Novo Nordisk INC | $666.52 | 2021-2025 | Ozempic, Rybelsus, Saxenda |
| Astrazeneca Pharmaceuticals LP | $242.50 | 2021-2022 | |
| Insulet Corporation | $137.14 | 2022 | |
| Dexcom, INC. | $133.65 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $118.26 | 2024 | |
| Amgen INC. | $110.34 | 2022-2025 | Tepezza |
| Lilly USA, LLC | $65.44 | 2022-2023 | Mounjaro, Trulicity |
| Sanofi-Aventis U.S. LLC | $64.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.39 | 2023-2025 | Jardiance, Synjardy |
| Radius Health, INC. | $38.24 | 2023 | Tymlos |
| Nevro Corp. | $19.36 | 2022 | |
| Viiv Healthcare Company | $19.24 | 2021 | |
| Zealand Pharma US, INC. | $17.77 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $16.39 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $15.13 | 2023 | Nocdurna, Tlando, Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $13.51 | 2022 | |
| Medtronic, INC. | $12.89 | 2023 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Eapen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.